CTAD 2022 – lecanemab data hold up, with a big but
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
Developers take another shot at an Alzheimer's vaccine
But the current leader, Vaxxinity, will have to convince its doubters if it is to hook a partner.
Gantenerumab fails to Graduate
Roche’s Alzheimer’s antibody looks likely to join the scrapheap. But the company is determined to keep plugging away at the disease.
Syncona sets its sights on a gene therapy turnaround
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
